Skip to main content
. 2019 Apr 2;14:2233–2251. doi: 10.2147/IJN.S195900

Figure 4.

Figure 4

(A) Viability of HepG2 cells treated with different inhibitors. (B) Effects of inhibitors on endocytosis in HepG2 cells. Significant difference from control: **P<0.01, ***P<0.001. (C) Confocal microscope images of HepG2 cells after pre-incubated with different inhibitors. Scale bar: 10 μm. (D) Confocal microscope images of HepG2 cells for intracellular delivery of C6-labeled MSNs, MSNs-GOx, MSNs-GOx/PLL and MSNs-GOx/PLL/HA for different times. The late endosomes and lysosomes were stained by Lyso-Tracker red. 1: overlay of 1, 2 and 3; 2: green fluorescent of C6-labeled nanoparticles; 3: red fluorescent of endo/lysosomes; 4: bright field of cells; 1 hour: incubation with nanoparticles for 1 hour, followed by imaged by CLSM; 1 +2 hours: incubation with nanoparticles for 1 hour, followed by washing and further incubation for 2 hours; 1 +4 hours: incubation with nanoparticles for 1 hour, followed by washing and further incubation for 4 hours; Scale bar: 10 μm.

Abbreviations: GOx, glucose oxidase; MSNs, mesoporous silica nanoparticles; MSNs-CHO, benzaldehyde-functionalized mesoporous silica nanoparticles; PLL, poly (L-lysine); HA, hyaluronic acid; C6, coumarin; CLSM, confocal laser scanning microscopy.